Oct. 14, days before the 2025 European Society for Medical Oncology (ESMO) Congress in Berlin, Merck & Co. | Merck has just ...

With the lupus treatment landscape poised for a shake-up, Roche is hitting t | Early Monday, Roche announced that the FDA ...

Merck has kicked off construction of a new $3 billion facility at its sprawling manufacturing campus in Elkton, Virginia. | ...

In Q3, the top 10 TV ad spenders poured a combined $544.8 million into airing their commercials, according to data shared ...

Theravance is educating physicians and payers in anticipation of phase 3 data on ampreloxetine in nOH due to MSA. The company ...

Susan Galbraith, Ph.D., AZ’s oncology R&D chief, attributed Datroway’s strong efficacy to its ADC construct, specifically its ...

After upstaging Merck & Co.’s Keytruda as a monotherapy for patients with first-line non-small cell lung cancer (NSCLC) in ...

Novartis has shared detailed data showing its radioligand therapy Pluvicto could slow the progression of certain hormone-sensitive prostate cancers ahead of a planned application with the FDA. | ...

Merck’s efforts to make headway in a cancer type that was an elusive target for its superstar oncology med Keytruda prove to ...

Sanofi gained Rezurock in a $1.9 billion buyout of Kadmon in 2021, less than two months after the FDA approved the treatment ...

AstraZeneca and Daiichi Sankyo’s star drug Enhertu has delivered a double knockout, showing its ability to stave off early ...

For years, MASH was where drug development dreams went to die.  | After Rezdiffra’s approval and Wegovy’s label expansion, ...